Samit Ghosal
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Samit Ghosal has a total of 109 co-authors. Here are the top co-authors by number of shared publications:
Binayak Sinha
Department of Endocrinology, Manipal Hospitals , Kolkata 700106
28 shared publications- Binayak Sinha
AMRI Hospitals
21 shared publications Anuradha Ghosal
Department of Medical Sciences, Aston Medical School, Aston University, Birmingham, UK, aston.ac.uk
5 shared publicationsDebasis Datta
Fortis Hospital, Kolkata, India
5 shared publicationsMilan Majumder
Milan Majumder, Independent Statistician, Pune, India
5 shared publications- Kalyan Kumar Gangopadhyay
Department of Endocrinology and Diabetes, Fortis Hospital, Kolkata, India
4 shared publications
Latest Publications
- Open Access
- 7 October 2026
- Published by Elsevier in Obesity Pillars
- Vol. 20
Determinants of variable response to GLP-1 receptor agonists: A mechanism-informed framework for precision treatment of obesity
- 7 October 2026
- Published by Elsevier in Obesity Pillars
- Vol. 20
Open AccessDeterminants of variable response to GLP-1 receptor agonists: A mechanism-informed framework for precision treatment of obesity
- Open Access
- 30 May 2026
- Published by Elsevier in Obesity Pillars
- Vol. 19
Effects of lifestyle and glucagon-like Peptide-1 receptor agonist-based therapies on waist circumference: A systematic review and meta-analysis
- 30 May 2026
- Published by Elsevier in Obesity Pillars
- Vol. 19
Open AccessEffects of lifestyle and glucagon-like Peptide-1 receptor agonist-based therapies on waist circumference: A systematic review and meta-analysis
- Open Access
- 5 March 2026
- Published by Oxford University Press (OUP) in European Heart Journal Open
- Vol. 6 (2)
Predicted cardiovascular risk reduction with tirzepatide vs. semaglutide: interpretative considerations from the SURMOUNT-5 post hoc analysis
- 5 March 2026
- Published by Oxford University Press (OUP) in European Heart Journal Open
- Vol. 6 (2)
Open AccessPredicted cardiovascular risk reduction with tirzepatide vs. semaglutide: interpretative considerations from the SURMOUNT-5 post hoc analysis
- Open Access
- 14 January 2026
- Published by Wiley in International Journal of Hepatology
- Vol. 2026 (1) , 9419416
Global Bivariate Meta‐Analysis of FIB‐4 Cut‐Offs to Rule Out Advanced Fibrosis in MASLD
Background: The fibrosis‐4 (FIB‐4) index, a non‐invasive marker, evaluates advanced fibrosis in metabolic dysfunction‐associated steatotic liver disease (MASLD), but the variability in its performance across different populations remains unclear. Methods: We conducted a systematic review and bivariate meta‐analysis of 14 studies ( N = 5521) with 2 × 2 contingency data for FIB‐4 at thresholds < 1.0 and < 1.3, compared with liver biopsy or transient elastography (TE). The Reitsma model (R v4.4.3) estimated pooled sensitivity and specificity. Subgroup analyses assessed region (India vs. global) and reference standard effects, with heterogeneity and publication bias (Deeks′ test) evaluated. Results: Pooled sensitivity was 0.73 (95% CI: 0.69–0.77), and specificity was 0.69 (95% CI: 0.61–0.76) at < 1.3. The < 1.0 threshold demonstrated higher specificity (0.83, 95% CI: 0.75–0.89) but lower sensitivity (0.63, 95% CI: 0.58–0.68). Indian cohorts ( n = 3) exhibited higher specificity (0.83) than the global estimate (0.66) at < 1.3, whereas sensitivity remained similar. Conclusion: FIB‐4 below 1.3 is a useful initial tool for ruling out advanced fibrosis in MASLD, with potential regional variations in specificity. Larger studies are needed to confirm cut‐offs, supporting tailored guidelines with sequential testing.
- 14 January 2026
- Published by Wiley in International Journal of Hepatology
- Vol. 2026 (1) , 9419416
Open AccessGlobal Bivariate Meta‐Analysis of FIB‐4 Cut‐Offs to Rule Out Advanced Fibrosis in MASLD
Background: The fibrosis‐4 (FIB‐4) index, a non‐invasive marker, evaluates advanced fibrosis in metabolic dysfunction‐associated steatotic liver disease (MASLD), but the variability in its performance across different populations remains unclear. Methods: We conducted a systematic review and bivariate meta‐analysis of 14 studies ( N = 5521) with 2 × 2 contingency data for FIB‐4 at thresholds < 1.0 and < 1.3, compared with liver biopsy or transient elastography (TE). The Reitsma model (R v4.4.3) estimated pooled sensitivity and specificity. Subgroup analyses assessed region (India vs. global) and reference standard effects, with heterogeneity and publication bias (Deeks′ test) evaluated. Results: Pooled sensitivity was 0.73 (95% CI: 0.69–0.77), and specificity was 0.69 (95% CI: 0.61–0.76) at < 1.3. The < 1.0 threshold demonstrated higher specificity (0.83, 95% CI: 0.75–0.89) but lower sensitivity (0.63, 95% CI: 0.58–0.68). Indian cohorts ( n = 3) exhibited higher specificity (0.83) than the global estimate (0.66) at < 1.3, whereas sensitivity remained similar. Conclusion: FIB‐4 below 1.3 is a useful initial tool for ruling out advanced fibrosis in MASLD, with potential regional variations in specificity. Larger studies are needed to confirm cut‐offs, supporting tailored guidelines with sequential testing.
- Open Access
- 5 December 2025
- Published by Springer Nature in Addiction Science & Clinical Practice
- Vol. 21 (1)
The effects of glucagon-like peptide-1 receptor agonists (GLP1-RAs) on alcohol-related outcomes: a systematic review and meta-analysis
Objective: To evaluate the effects of glucagon-like peptide-1 receptor agonists (GLP-1RAs) on alcohol-related outcomes in adults with or without alcohol use disorder (AUD). Methods: A systematic review and meta-analysis following PRISMA guidelines searched PubMed, Embase, and Cochrane Library up to May 3, 2025. Eligible studies included randomized controlled trials (RCTs) and observational studies assessing GLP-1RAs (e.g., Semaglutide, Liraglutide, Exenatide, and Dulaglutide) versus placebo, no treatment, or other interventions in adults. Outcomes were alcohol consumption (defined as total intake or drinks per drinking day, measured as standardised mean difference [SMD]), alcohol craving (SMD), and alcohol-related events (hazard ratio [HR]). Random-effects models with Restricted Maximum Likelihood estimation and Hartung-Knapp adjustment were used. Separate AUD and SUD meta-analyses addressed outcome heterogeneity, with intoxication reported narratively. Results: Three RCTs ( N = 430) and six observational studies ( N = 2,740,207) were included. RCTs showed non-significant reductions in alcohol consumption (SMD: -0.24, 95% CI: -0.70, 0.23), drinks per drinking day (SMD: -0.23, 95% CI: -0.64, 0.19), and craving (SMD: -0.14, 95% CI: -2.84, 2.55), with Semaglutide showing greater craving reduction ( p = 0.024). Observational studies showed reduced alcohol-related events (HR: 0.64, 95% CI: 0.59–0.69, p < 0.001), with separate analyses confirming effects for AUD (HR: 0.66, 95% CI: 0.63–0.70) and SUD (HR: 0.66, 95% CI: 0.18–2.48), and intoxication (HR: 0.50). Semaglutide and GIP/GLP-1RAs had more potent effects ( p < 0.001). Conclusion: Observational studies suggest a decrease in alcohol-related events, but RCTs have effects on alcohol consumption and craving that remain non-significant. Larger RCTs are needed. PROSPERO ID: CRD420251045294.
- 5 December 2025
- Published by Springer Nature in Addiction Science & Clinical Practice
- Vol. 21 (1)
Open AccessThe effects of glucagon-like peptide-1 receptor agonists (GLP1-RAs) on alcohol-related outcomes: a systematic review and meta-analysis
Objective: To evaluate the effects of glucagon-like peptide-1 receptor agonists (GLP-1RAs) on alcohol-related outcomes in adults with or without alcohol use disorder (AUD). Methods: A systematic review and meta-analysis following PRISMA guidelines searched PubMed, Embase, and Cochrane Library up to May 3, 2025. Eligible studies included randomized controlled trials (RCTs) and observational studies assessing GLP-1RAs (e.g., Semaglutide, Liraglutide, Exenatide, and Dulaglutide) versus placebo, no treatment, or other interventions in adults. Outcomes were alcohol consumption (defined as total intake or drinks per drinking day, measured as standardised mean difference [SMD]), alcohol craving (SMD), and alcohol-related events (hazard ratio [HR]). Random-effects models with Restricted Maximum Likelihood estimation and Hartung-Knapp adjustment were used. Separate AUD and SUD meta-analyses addressed outcome heterogeneity, with intoxication reported narratively. Results: Three RCTs ( N = 430) and six observational studies ( N = 2,740,207) were included. RCTs showed non-significant reductions in alcohol consumption (SMD: -0.24, 95% CI: -0.70, 0.23), drinks per drinking day (SMD: -0.23, 95% CI: -0.64, 0.19), and craving (SMD: -0.14, 95% CI: -2.84, 2.55), with Semaglutide showing greater craving reduction ( p = 0.024). Observational studies showed reduced alcohol-related events (HR: 0.64, 95% CI: 0.59–0.69, p < 0.001), with separate analyses confirming effects for AUD (HR: 0.66, 95% CI: 0.63–0.70) and SUD (HR: 0.66, 95% CI: 0.18–2.48), and intoxication (HR: 0.50). Semaglutide and GIP/GLP-1RAs had more potent effects ( p < 0.001). Conclusion: Observational studies suggest a decrease in alcohol-related events, but RCTs have effects on alcohol consumption and craving that remain non-significant. Larger RCTs are needed. PROSPERO ID: CRD420251045294.
- Open Access
- 7 November 2025
- Published by Springer Nature in Diabetes Therapy
- Vol. 17 (1) , 55-72
Risk–Benefit Trade-offs of GLP-1RAs and SGLT-2is in Type 2 Diabetes Mellitus (T2D): Systematic Review, Meta-Analysis, and Net Benefit Modeling
Introduction While glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT-2is) are established for cardiorenal benefits in type 2 diabetes mellitus (T2DM), prior meta-analyses have not fully integrated cross-class comparisons or net benefit analyses with updated cardiovascular outcome trials (CVOTs). Methods We conducted a systematic review and meta-analysis of 17 CVOTs (N = 132,038; GLP-1RA: N = 73,263; SGLT-2i: N = 58,775) using PubMed and Cochrane CENTRAL. We uniquely synthesized major adverse cardiovascular events (MACE), hospitalization for heart failure (hHF), renal composites, and safety outcomes (e.g., retinopathy, genitourinary infections) with random-effects models for hazard ratios (HRs) and relative risks (RRs). Innovative graphical syntheses (tornado/scatter plots, risk curves) and net benefit calculations (absolute risk reductions [ARRs] minus absolute excess risks [AERs]) were employed. Risk of bias (RoB 2) and GRADE certainty were assessed. Results Both classes reduced MACE (HR 0.87, 95% CI 0.84–0.90; p = 0.73 for class difference). SGLT-2is were superior for hHF (HR 0.69 vs. 0.88, p < 0.0001) and renal outcomes (HR 0.68 vs. 0.79, p = 0.026). GLP-1RAs increased retinopathy (RR 1.18, AER + 6.5/1000); SGLT-2is increased genitourinary infections (RR 3.34, AER + 19.9/1000) and DKA (RR 2.67, AER + 1.2/1000). Amputation signals attenuated post-sensitivity analysis. Net benefits favored GLP-1RAs for MACE (+ 2.5/1000). For SGLT-2is, base-case estimates using genital-mycotic infections as the sentinel harm were marginal (hHF: − 4.9/1000; renal: − 1.9/1000), whereas sensitivity scenarios with alternative harms (e.g., volume depletion, amputation, DKA) yielded positive net benefits. GRADE certainty was high for efficacy, moderate for harms. Conclusions Our innovative integration of updated CVOTs, cross-class comparisons, and graphical risk–benefit tools refines therapeutic decision-making, highlighting tailored T2DM management based on patient-specific cardiorenal risks. Trial Registration PROSPERO (CRD420251146788).
- 7 November 2025
- Published by Springer Nature in Diabetes Therapy
- Vol. 17 (1) , 55-72
Open AccessRisk–Benefit Trade-offs of GLP-1RAs and SGLT-2is in Type 2 Diabetes Mellitus (T2D): Systematic Review, Meta-Analysis, and Net Benefit Modeling
Introduction While glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT-2is) are established for cardiorenal benefits in type 2 diabetes mellitus (T2DM), prior meta-analyses have not fully integrated cross-class comparisons or net benefit analyses with updated cardiovascular outcome trials (CVOTs). Methods We conducted a systematic review and meta-analysis of 17 CVOTs (N = 132,038; GLP-1RA: N = 73,263; SGLT-2i: N = 58,775) using PubMed and Cochrane CENTRAL. We uniquely synthesized major adverse cardiovascular events (MACE), hospitalization for heart failure (hHF), renal composites, and safety outcomes (e.g., retinopathy, genitourinary infections) with random-effects models for hazard ratios (HRs) and relative risks (RRs). Innovative graphical syntheses (tornado/scatter plots, risk curves) and net benefit calculations (absolute risk reductions [ARRs] minus absolute excess risks [AERs]) were employed. Risk of bias (RoB 2) and GRADE certainty were assessed. Results Both classes reduced MACE (HR 0.87, 95% CI 0.84–0.90; p = 0.73 for class difference). SGLT-2is were superior for hHF (HR 0.69 vs. 0.88, p < 0.0001) and renal outcomes (HR 0.68 vs. 0.79, p = 0.026). GLP-1RAs increased retinopathy (RR 1.18, AER + 6.5/1000); SGLT-2is increased genitourinary infections (RR 3.34, AER + 19.9/1000) and DKA (RR 2.67, AER + 1.2/1000). Amputation signals attenuated post-sensitivity analysis. Net benefits favored GLP-1RAs for MACE (+ 2.5/1000). For SGLT-2is, base-case estimates using genital-mycotic infections as the sentinel harm were marginal (hHF: − 4.9/1000; renal: − 1.9/1000), whereas sensitivity scenarios with alternative harms (e.g., volume depletion, amputation, DKA) yielded positive net benefits. GRADE certainty was high for efficacy, moderate for harms. Conclusions Our innovative integration of updated CVOTs, cross-class comparisons, and graphical risk–benefit tools refines therapeutic decision-making, highlighting tailored T2DM management based on patient-specific cardiorenal risks. Trial Registration PROSPERO (CRD420251146788).
- Open Access
- 1 November 2025
- Published by Taylor & Francis in Diabetes, Metabolic Syndrome and Obesity
- Vol. ume 18, 4347-4358
Optimising GLP-1RA Efficacy: A Meta-Analysis of Baseline Age and HbA1c as Predictors of MACE Reduction in T2DM
Background: Type 2 diabetes mellitus (T2DM) increases major adverse cardiovascular event (MACE) risk, requiring effective interventions. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) reduce MACE, but the impact of baseline characteristics on their efficacy is unclear from previous analyses. Methods: This PRISMA-guided systematic review and meta-analysis included randomised controlled trials (RCTs) comparing GLP-1RAs with placebo in patients with T2DM, sourced from PubMed and Google Scholar. We extracted MACE hazard ratios (HR), 95% confidence intervals (CI), and baseline characteristics (age, BMI, SBP, HbA1c, eGFR, male proportion, diabetes duration, CVD prevalence). A random-effects model estimated pooled HR, with heterogeneity assessed via prediction intervals. Meta-regression identified moderators. Sensitivity analyses and the RoB 2 Tool assessed bias; GRADE evaluated the certainty of evidence. Results: Across 11 RCTs (83,536 participants), the pooled HR for MACE was 0.87 (95% CI: 0.81– 0.93), indicating a 13% risk reduction with moderate heterogeneity (prediction interval: 0.79– 0.96). After excluding T2DM duration due to multicollinearity, multivariate meta-regression identified age (p = 0.02) and HbA1c (p = 0.03) as significant moderators, which persisted after excluding FREEDOM-CVO (age, p = 0.03; HbA1c, p = 0.04). Baseline CVD prevalence did not moderate outcomes (p = 0.892). Bias was low; evidence certainty was moderate. Conclusion: GLP-1RAs reduce MACE in T2DM, particularly in older patients with lower baseline HbA1c. This fills a critical gap in prior meta-analyses by identifying actionable pre-treatment predictors that support personalised therapy. Protocol Registration: Ghosal et al INPLASY protocol 202580045. doi:10.37766/inplasy2025.8.0045 INPLASY202580045.
- 1 November 2025
- Published by Taylor & Francis in Diabetes, Metabolic Syndrome and Obesity
- Vol. ume 18, 4347-4358
Open AccessOptimising GLP-1RA Efficacy: A Meta-Analysis of Baseline Age and HbA1c as Predictors of MACE Reduction in T2DM
Background: Type 2 diabetes mellitus (T2DM) increases major adverse cardiovascular event (MACE) risk, requiring effective interventions. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) reduce MACE, but the impact of baseline characteristics on their efficacy is unclear from previous analyses. Methods: This PRISMA-guided systematic review and meta-analysis included randomised controlled trials (RCTs) comparing GLP-1RAs with placebo in patients with T2DM, sourced from PubMed and Google Scholar. We extracted MACE hazard ratios (HR), 95% confidence intervals (CI), and baseline characteristics (age, BMI, SBP, HbA1c, eGFR, male proportion, diabetes duration, CVD prevalence). A random-effects model estimated pooled HR, with heterogeneity assessed via prediction intervals. Meta-regression identified moderators. Sensitivity analyses and the RoB 2 Tool assessed bias; GRADE evaluated the certainty of evidence. Results: Across 11 RCTs (83,536 participants), the pooled HR for MACE was 0.87 (95% CI: 0.81– 0.93), indicating a 13% risk reduction with moderate heterogeneity (prediction interval: 0.79– 0.96). After excluding T2DM duration due to multicollinearity, multivariate meta-regression identified age (p = 0.02) and HbA1c (p = 0.03) as significant moderators, which persisted after excluding FREEDOM-CVO (age, p = 0.03; HbA1c, p = 0.04). Baseline CVD prevalence did not moderate outcomes (p = 0.892). Bias was low; evidence certainty was moderate. Conclusion: GLP-1RAs reduce MACE in T2DM, particularly in older patients with lower baseline HbA1c. This fills a critical gap in prior meta-analyses by identifying actionable pre-treatment predictors that support personalised therapy. Protocol Registration: Ghosal et al INPLASY protocol 202580045. doi:10.37766/inplasy2025.8.0045 INPLASY202580045.
- 23 August 2025
- Published by International Platform of Registered Systematic Review and Meta-analysis Protocols (INPLASY)
Effects of Lifestyle and GLP-1RA based Interventions on Waist Circumference: A Systematic Review and Meta-Analysis
INPLASY202580071 Effects of Lifestyle and GLP-1RA based Interventions on Waist Circumference: A Systematic Review and Meta-Analysis Keywords: waist circumference; visceral adipose tissue; GLP-1 rec…
- 23 August 2025
- Published by International Platform of Registered Systematic Review and Meta-analysis Protocols (INPLASY)
Effects of Lifestyle and GLP-1RA based Interventions on Waist Circumference: A Systematic Review and Meta-Analysis
INPLASY202580071 Effects of Lifestyle and GLP-1RA based Interventions on Waist Circumference: A Systematic Review and Meta-Analysis Keywords: waist circumference; visceral adipose tissue; GLP-1 rec…
- 14 August 2025
- Published by International Platform of Registered Systematic Review and Meta-analysis Protocols (INPLASY)
Unveiling the Power of GLP-1RAs: Optimizing MACE Reduction in T2DM Through BMI and Blood Pressure Insights
INPLASY202580045 Optimizing GLP-1RA Efficacy: A Meta-Analysis of Baseline Age and HbA1c as Predictors of MACE Reduction in T2DM Keywords: GLP-1 receptor agonists; Type 2 diabetes mellitus; Major ad…
- 14 August 2025
- Published by International Platform of Registered Systematic Review and Meta-analysis Protocols (INPLASY)
Unveiling the Power of GLP-1RAs: Optimizing MACE Reduction in T2DM Through BMI and Blood Pressure Insights
INPLASY202580045 Optimizing GLP-1RA Efficacy: A Meta-Analysis of Baseline Age and HbA1c as Predictors of MACE Reduction in T2DM Keywords: GLP-1 receptor agonists; Type 2 diabetes mellitus; Major ad…
Efficacy and Safety of GLP ‐1 Receptor Agonists, Dual Agonists, and Retatrutide for Weight Loss in Adults With Overweight or Obesity: A Bayesian NMA
Objective: To compare the efficacy and safety of GLP‐1 receptor agonists (GLP‐1RAs), dual agonists (GLP‐1RAs/GIP or GCGR), and retatrutide (GLP‐1/GIP/glucagon) for weight loss in adults with overweight or obesity. Methods: We conducted a systematic review and Bayesian network meta‐analysis (NMA) of 19 randomized controlled trials (RCTs) including 29,506 adults (BMI ≥ 25 kg/m 2 ), assessing liraglutide, semaglutide, survodutide, tirzepatide, retatrutide, and placebo. Outcomes included mean weight loss, achievement of ≥ 5%, ≥ 10%, and ≥ 15% weight loss, waist circumference (WC), BMI, and adverse events (AEs) at ≥ 36 weeks. Subgroup and meta‐regression analyses evaluated the impact of diabetes status, sex, age, and BMI. Results: Retatrutide and dual agonists achieved equivalent mean weight loss (−11.0 kg), surpassing GLP‐1RAs (−9.0 kg), with retatrutide excelling at achieving ≥ 15% weight loss (OR 54.6). Dual agonists and GLP‐1RAs followed (OR 16.4 and 9.0, respectively). Retatrutide had the highest AE risk. Meta‐regression showed type 2 diabetes mellitus (T2DM) reduced weight loss by 4.338 kg for GLP‐1RAs and 5.016 kg for dual agonists, with enhanced outcomes in female‐dominant or high‐BMI cohorts. Conclusions: Retatrutide offers superior weight loss efficacy but with a higher AE risk. Dual agonists provide a favorable efficacy–safety balance. Personalized treatment selection based on patient characteristics is recommended. image
Efficacy and Safety of GLP ‐1 Receptor Agonists, Dual Agonists, and Retatrutide for Weight Loss in Adults With Overweight or Obesity: A Bayesian NMA
Objective: To compare the efficacy and safety of GLP‐1 receptor agonists (GLP‐1RAs), dual agonists (GLP‐1RAs/GIP or GCGR), and retatrutide (GLP‐1/GIP/glucagon) for weight loss in adults with overweight or obesity. Methods: We conducted a systematic review and Bayesian network meta‐analysis (NMA) of 19 randomized controlled trials (RCTs) including 29,506 adults (BMI ≥ 25 kg/m 2 ), assessing liraglutide, semaglutide, survodutide, tirzepatide, retatrutide, and placebo. Outcomes included mean weight loss, achievement of ≥ 5%, ≥ 10%, and ≥ 15% weight loss, waist circumference (WC), BMI, and adverse events (AEs) at ≥ 36 weeks. Subgroup and meta‐regression analyses evaluated the impact of diabetes status, sex, age, and BMI. Results: Retatrutide and dual agonists achieved equivalent mean weight loss (−11.0 kg), surpassing GLP‐1RAs (−9.0 kg), with retatrutide excelling at achieving ≥ 15% weight loss (OR 54.6). Dual agonists and GLP‐1RAs followed (OR 16.4 and 9.0, respectively). Retatrutide had the highest AE risk. Meta‐regression showed type 2 diabetes mellitus (T2DM) reduced weight loss by 4.338 kg for GLP‐1RAs and 5.016 kg for dual agonists, with enhanced outcomes in female‐dominant or high‐BMI cohorts. Conclusions: Retatrutide offers superior weight loss efficacy but with a higher AE risk. Dual agonists provide a favorable efficacy–safety balance. Personalized treatment selection based on patient characteristics is recommended. image